The mammalian target of rapamycin (mTOR) is a downstream effector of the phosphatidylinositol 3-kinase (PI3K)/Akt (protein kinase B) signaling pathway that mediates cell survival and proliferation. It is increasingly apparent that mTOR signaling impacts most major cellular functions. Because mTOR deregulation occurs in human disease, including cancer, obesity, type 2 diabetes, and neurodegeneration, there are significant ongoing efforts to pharmacologically target the mTOR pathway (1). Treatment with polyphenols in various prostate cancer cell lines showed a decrease in the mTOR levels as detected...